15 Cancer Drugs Are in Short Supply, FDA reports: The Kiplinger Letter
The U.S. is working to address cancer drug shortages caused by manufacturing and supply chain woes.
To help you understand what the U.S. is doing to address problems and challenges in the healthcare sector, our highly experienced Kiplinger Letter team will keep you abreast of the latest developments and forecasts (Get a free issue of The Kiplinger Letter or subscribe). You'll get all the latest news first by subscribing, but we will publish many (but not all) of the forecasts a few days afterward online. Here’s the latest…
Uncle Sam has made some progress in reducing cancer drug shortages by working with manufacturers to restart U.S. production facilities that were previously shut down, as well as securing vital overseas supplies.
One drug, cisplatin, often used to treat ovarian, bladder and testicular cancer has already returned to near 100% pre-shortage levels of supply. However, The U.S. still has an overall shortage of 15 cancer drugs, per the Food and Drug Administration (FDA), because of manufacturing and supply chain problems.
![https://cdn.mos.cms.futurecdn.net/hwgJ7osrMtUWhk5koeVme7-200-80.png](https://cdn.mos.cms.futurecdn.net/hwgJ7osrMtUWhk5koeVme7-320-80.png)
Sign up for Kiplinger’s Free E-Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
In 2022, manufacturing site closures reduced the U.S. supply of cisplatin, (used to treat bladder cancer, testicular cancer, or ovarian cancer), carboplatin (used for ovarian cancer) and methotrexate (used for leukemia, breast and lung cancer, and more) by nearly half, leading to treatment delays for cancer patients.
One survey by the National Comprehensive Cancer Network in June found that 70% of its members were experiencing a cisplatin shortage, while virtually all their members found carboplatin difficult to come by. Around 20% of cancer patients rely on platinum-based chemotherapy drugs, such as cisplatin and carboplatin, for treatment, according to federal health statistics.
Several U.S. manufacturers have exited this market in recent years, increasing American reliance on foreign imports from China and India, in particular. It remains unclear how Uncle Sam will address this long-term problem, which may ultimately require using government demand to bolster manufacturing.
One bill now under consideration by Congress, the Drug Shortage Prevention Act, would require manufacturers to report anticipated shortages ahead of time.
This forecast first appeared in The Kiplinger Letter, which has been running since 1923 and is a collection of concise weekly forecasts on business and economic trends, as well as what to expect from Washington, to help you understand what’s coming up to make the most of your investments and your money. Subscribe to The Kiplinger Letter.
Related Content
- Costs of 34 Medicare Drugs To Be Capped Until December
- Select Health Aims to Offer Lower Drug Prices Via New Partnership
- How to Save on Prescription Medication
To continue reading this article
please register for free
This is different from signing in to your print subscription
Why am I seeing this? Find out more here
Get Kiplinger Today newsletter — free
Profit and prosper with the best of Kiplinger's advice on investing, taxes, retirement, personal finance and much more. Delivered daily. Enter your email in the box and click Sign Me Up.
-
Amazon Prime Day 2024: Should You Sign Up Before the Big Sale?
Becoming an Amazon Prime member affords you dozens of perks. With Prime Day 2024 coming up July 16 and 17, is it worth it to sign up before the big sale?
By Kathryn Pomroy Published
-
10 Ways to Generate Retirement Income
Here are some of the benefits and drawbacks of each of these retirement income strategies so you can see which ones might work for you.
By Mike Decker, NSSA® Published
-
Kiplinger Special: The Long-Term Future of the U.S. Economy
The Kiplinger Letter Kiplinger's report into what it will take the U.S. to maintain a healthy economic growth rate.
By David Payne Published
-
Chinese E-Tailers Are Surging in the U.S. Market: The Kiplinger Letter
The Kiplinger Letter Low costs and cheap shipping enable Temu and others to grab market share.
By Matthew Housiaux Published
-
Why Your Electric Bill Will Keep Climbing
The Kiplinger Letter There's no end in sight for energy rate hikes, so look for ways to curb your power use.
By Jim Patterson Published
-
Future U.S. Economic Growth Hinges on Immigrants
The Kiplinger Letter With the native birthrate slipping, employers are increasingly relying on foreign-born workers to staff up.
By David Payne Published
-
Fed Rate Cuts Still on Hold
The Kiplinger Letter With inflation stubbornly elevated, the Federal Reserve will keep interest rates high for now.
By David Payne Published
-
A Spotlight on the Pacific States: The Kiplinger Letter
The Kiplinger Letter Most Pacific states are seeing good job growth in multiple sectors including tourism, hospitality, and construction.
By David Payne Published
-
The Robots Are Coming... But Not For a While
The Kiplinger Letter There’s excitement in the tech sector over the potential of humanoid robots, but widespread adoption is likely to be years away.
By John Miley Published
-
Farmers Face Another Tough Year As Costs Continue to Climb: The Kiplinger Letter
The Kiplinger Letter Farm income is expected to decline for a second year, while costs continue to up-end farm profitability.
By Matthew Housiaux Published